Nyxoah to Release Second Quarter 2025 Financial Results
Nyxoah, known for its innovative solutions in treating Obstructive Sleep Apnea (OSA), has disclosed that it will publish its financial results for the second quarter of 2025 on the upcoming Monday, August 18, 2025. This announcement underlines the company's dedication to transparency and stakeholder engagement.
Conference Call Details
On the same day, the management team will host a conference call to discuss these financial results, scheduled to begin at 10:30 PM CET / 4:30 PM ET. This call is an essential opportunity for analysts and investors to gain insights into the company's performance and future directions.
Webcast Access Information
For those interested in tuning in, the conference call will be available via a webcast hosted on the Nyxoah Investor Relations page. This format is encouraged, especially for participants not seeking to pose questions directly during the call.
Joining the Conference
If you wish to ask questions during the conference, please register using the provided link. An email confirming your registration will include the necessary dial-in information and a unique access code to join the live discussion. To ensure proper connectivity, it is recommended to join at least 10 minutes prior to the start time.
Company Overview
Nyxoah is a trailblazer in developing advanced therapeutic solutions for treating OSA, primarily through its flagship product, the Genio system. This groundbreaking therapy involves a leadless, battery-free hypoglossal neurostimulation device that aims to improve patients' quality of sleep drastically. Highlighting its significance, OSA is recognized as a leading cause of serious health risks like mortality and cardiovascular issues.
Significant Advances and Achievements
Since receiving the European CE Mark in 2019 following the successful BLAST OSA study, Nyxoah has made remarkable strides. The company successfully executed initial public offerings on Euronext Brussels in September of 2020 and NASDAQ in July 2021. Recently, following favorable outcomes from the BETTER SLEEP study, Nyxoah earned CE mark approval to extend its treatment applications to include patients with Complete Concentric Collapse (CCC), previously deemed unsuitable for competitor treatments.
Future Prospects
The company is continuously focused on enhancing its offerings and expanding its market reach. Currently, Nyxoah is working on various clinical studies and actively seeking FDA approval, emphasizing its commitment to adapting and meeting market needs. The management remains optimistic about the path ahead, hopeful for further advancements that could expand their patient base significantly.
Contact Information
For more inquiries, interested parties can reach out to Nyxoah directly. Contact John Landry, the CFO, via email at IR@nyxoah.com. You can also connect with Anne Hennecke from MC Services at nyxoah@mc-services.eu for international media inquiries.
Frequently Asked Questions
What is the significance of the Q2 2025 financial results for Nyxoah?
The Q2 2025 financial results will provide insights into Nyxoah's performance, including revenue growth and developments in their product offerings.
How can investors listen to the Nyxoah conference call?
Investors can listen to the conference call via the webcast available on Nyxoah's Investor Relations page.
What are Nyxoah’s main products?
Nyxoah's flagship product is the Genio system, an innovative therapy for treating Obstructive Sleep Apnea through neurostimulation.
When did Nyxoah get the CE mark for the Genio system?
Nyxoah received the European CE Mark for the Genio system in 2019.
How does Nyxoah plan to expand its market presence?
Nyxoah is focusing on ongoing clinical studies and regulatory approvals to broaden its patient base and product offerings.
